Veracyte
Veracyte, Inc. is a genomic diagnostics company based in South San Francisco, California, that specializes in providing advanced diagnostic solutions for cancer and other diseases. Its product offerings include the Afirma Genomic Sequencing Classifier, which helps identify benign thyroid nodules, the Percepta Genomic Sequencing Classifier for lung cancer, and the Envisia Genomic Classifier for distinguishing idiopathic pulmonary fibrosis from other interstitial lung diseases. Additionally, Veracyte offers the Prosigna Breast Cancer Prognostic Gene Signature Assay, which assesses the risk of distant recurrence in breast cancer patients. The company's tests leverage advances in genomic science to reduce the need for invasive procedures, thereby facilitating timely and accurate treatment decisions. Veracyte has established collaborations with Johnson & Johnson Innovation and Loxo Oncology to enhance its diagnostic capabilities and develop targeted therapies for genetically defined cancers. Since its incorporation in 2006 and subsequent name change in 2008, Veracyte has aimed to improve patient care through innovative genomic testing.
Top Stages
4 past transactions
C2i Genomics
Acquisition in 2024
C2i Genomics, Inc. is a biotechnology company that specializes in whole genome analysis solutions aimed at monitoring tumor recurrence in post-resection cancer patients. Founded in 2019 and based in New York with a research and development center in Haifa, Israel, the company offers liquid biopsy services that detect subtle changes in tumor DNA to assess cancer recurrence and progression. Its technology supports a bio-platform approach applicable across various cancer types, enhancing the effectiveness of treatments such as surgery, chemotherapy, immunotherapy, and targeted therapies. Additionally, C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations, enabling healthcare professionals to monitor treatment responses and detect potential treatment failures or disease recurrence more effectively than traditional methods.
Qiagen Marseille
Acquisition in 2021
HalioDx is a biotechnology company focused on developing diagnostic tests for oncology that analyze the immune contexture of cancers. The company creates a range of immunologic scoring tests aimed at investigating the immune response within the tumor microenvironment. These tests leverage a proprietary set of immune biomarkers and advanced image analysis technologies to accurately measure the immune reaction in and around tumors. By providing insights into the severity of a patient's disease and predicting their response to treatment, HalioDx seeks to enhance clinical decision-making and improve patient outcomes in cancer care.
Decipher Biosciences
Acquisition in 2021
Decipher Biosciences, Inc. is a genomic information company focused on the development and commercialization of clinical tests for urologic cancers. The company specializes in providing genomic tests such as Decipher Prostate Biopsy, which analyzes tumor tissue to tailor treatment based on the metastatic potential of prostate cancer. Additionally, Decipher Bladder offers genomic subtyping for muscle-invasive bladder cancer, assisting healthcare providers in determining which patients may benefit from neoadjuvant chemotherapy before radical cystectomy. Founded in 2008 and headquartered in San Diego, California, Decipher Biosciences also operates a research and development center in Vancouver, Canada. The company is actively expanding its GRID database, which consists of over 70,000 whole transcriptome profiles, and collaborates with pharmaceutical companies to identify biomarkers for new therapeutic responses.
Allegro Diagnostics
Acquisition in 2014
Allegro Diagnostics, founded in 2006 by Dr. Jerome Brody and Dr. Avrum Spira, is a molecular diagnostics company based in Maynard, Massachusetts. The firm specializes in the development and commercialization of advanced genomic tests aimed at diagnosing, staging, and guiding treatment for lung cancer and other lung diseases. Utilizing a proprietary molecular testing platform, Allegro analyzes specific changes in gene expression within airway epithelial cells to detect early signs of lung cancer, particularly in current and former smokers. This innovative approach provides healthcare professionals with essential diagnostic information, facilitating quicker diagnosis and more effective treatment options for patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.